No Data
No Data
GTJA: Innovent Bio's Marziditide is expected to be approved by 25H1, maintaining a "shareholding" rating.
GTJA released a research report stating that Innovent Bio (01801) had intensive clinical data readings on its integrated pipeline and tumor pipeline. PD-1/IL2, CLND18.2ADC, and CLDN18.2/CD3 clinical data were excellent, and Marizomib is expected to be approved soon with enormous market potential. GTJA maintains a 'shareholding' rating, stating that it is optimistic about the company's integrated pipeline and Marizomib's layout in the IO+ADC tumor field, and its increase in domestic sales. GTJA's main viewpoints are as follows: Marizomib effectively reduces weight and decreases liver fat by more than 80%, indicating its potential entry into the MASH treatment market. According to GLOR.
Alnylam, Lilly, AstraZeneca Among Best Performing Pharmas, Biotechs in Q2
The Top Country With Most Scientists per Capita in the World
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
Novo Nordisk Options Trading: A Deep Dive Into Market Sentiment
Novo Nordisk Fully Valued Amid Limited Longer-Term Visibility -- Market Talk
Art of Trading RA : Very good, well done
, lots to understand from your trades.
约翰の理财库OP Art of Trading RA: Thank you![undefined undefined](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
I love birds 约翰の理财库OP: hello bro , do you think this is a good idea ?
I love birds : btw congratulations for your 88k profit
约翰の理财库OP I love birds: Money market offer a safe and stable investment option for money you may need to access in the short term(not for long term) but liquidable T+0 day
View more comments...